News
Magda Martí, new managing director of IDIBELL
Today September 20th, Ms. Magda Martí has been officially presented as the new Managing Director of IDIBELL to all administration and service staff. Martin joined IDIBELL last September 12th replacing Mr. Alexandre Puerto. Magda Martí comes from the Quality and Health Assessment Agency of Catalonia (AQuAS), where she worked for more than eight years as […]
INPhINIT, the new ”la Caixa” Doctoral Fellowship Programme
INPhINIT a new doctoral fellowship programme international Early-Stage Researchers supporting the best scientific talent fostering innovative and high-quality research in Spain 57 Early-Stage Researchers of any nationality, 3-year employment contract at the Research Centre of their choice personal career development plan mobility opportunities, complementary training courses and workshops. European Commission’s support Horizon 2020 Marie Skłodowska-Curie Actions – COFUND programme highest standards for research training
Dr. Conxi Lázaro is awarded the Theodor Schwann Prize for his research in the field of neurofibromatosis
Dr. Conxi Lázaro, director of the Molecular Diagnostic Unit of the ICO-IDIBELL Hereditary Cancer Program, has received the prestigious Theodor Schwann prize awarded by the European Association of Neurofibromatosis. This award is named after the German physiologist who identified the cells responsible for tumors present in patients with neurofibromatosis type 1, the Schwann cells. Dr. […]
Catalonia’s Parliament awards its medal of honor to IDIBELL’s researcher Manel Esteller
Catalonia’s parliament has given today, as part of the celebration of the National Day of Catalonia, the medal of honor in the category of gold to Dr. Manel Esteller, “for his career as a Catalan physician and researcher of international reference”. During the ceremony, the president Carmen Forcadell, and the president of the Generalitat, Carles […]
Tumor microenvironment acts as a mechanism of resistance to chemotherapy in colorectal cancer
A new study highlights the importance of the tumor environment as a source of resistance to treatment in colorectal cancer, the fourth most common cancer and the leading cause of cancer death worldwide.
The first epigenetic test to identify tumors of unknown primary
The EPICUP® test is a new tool that helps identify up to 87% of cases of cancer of unknown origin (CUP) Article Esteller M The Lancet Oncology
Not all tumor cells are equal
Scientists find that colorectal tumors present epigenetic heterogeneity relates to the clinical course of the disease. Article citation Esteller M Gastroenterology